Maternal-Fetal Medicine · Clinical Presentation

Pre-Gestational
Type 2 Diabetes
in Pregnancy

Clinical Management · Pharmacology · Surveillance

ACOG SMFM Endocrine Society 2024–2025 Evidence-Based Practice
Use ← → arrow keys or buttons below to navigate

Early Hyperglycemia Drives Congenital Risk

Organogenesis occurs weeks 3–8. First-trimester HbA1c is the primary determinant of major congenital anomaly risk.

HbA1c < 6.5%
Low
HbA1c 6.5–8%
Moderate
HbA1c 8–10%
High
HbA1c > 10%
Very High

Relative congenital anomaly risk gradient by first-trimester HbA1c

Diagnosis Before 15 Weeks = Pre-Gestational T2DM

HbA1c
≥ 6.5%
Fasting Plasma Glucose
≥ 126 mg/dL
2-hr 75g OGTT
≥ 200 mg/dL
Conception
0 wks
Pre-gestational
T2DM window
< 15 wks
GDM Screen
24–28 wks
Delivery
39 wks

HbA1c < 6.5% Before Conception Reduces Anomaly Risk

Preconception Target
HbA1c < 6.5%
Reduces spontaneous abortion & major congenital anomalies
Caution Below 6.0%
HbA1c < 6.0%
Increased maternal hypoglycemia risk — balance is essential

Preconception counseling and optimization are the most impactful interventions available.

Stringent Targets Prevent Macrosomia & Neonatal Hypoglycemia

Measurement Target (mg/dL) Target (mmol/L) Clinical Goal
Fasting < 95 5.3 Prevent overnight hyperglycemia
1-hr Postprandial < 140 7.8 Limit postmeal glucose excursion
2-hr Postprandial < 120 6.7 Confirm glucose return to baseline

Source: ACOG Practice Bulletin · Endocrine Society Clinical Practice Guideline

Insulin Does Not Cross the Placenta — First-Line Choice

💉
Insulin
↓
Placenta
✕
No transfer
No placental transfer — no direct fetal drug exposure
Reduces macrosomia and large-for-gestational-age (LGA) infants
Robust safety profile across all trimesters
Multiple daily injections required; hypoglycemia risk — educate patients
ACOG First-Line  SMFM Endorsed  Endocrine Society 2024–2025

Metformin Crosses the Placenta — Benefits vs. Risks Must Be Weighed

Benefits

  • ↓ Total daily insulin dose
  • ↓ Maternal weight gain
  • ↓ LGA infants (MiTy trial)
  • Potential ↓ cesarean delivery rate
⚖

Risks

  • Readily crosses placenta
  • ↑ SGA infants (MiTy trial)
  • Altered offspring body composition
  • Long-term childhood metabolic effects uncertain
Endocrine Society 2024–2025: Do not routinely add metformin to insulin in pre-gestational T2DM

Guideline Preference Is Clear — Insulin Remains Mainstay

Feature Insulin Metformin
Placental Transfer None Readily crosses
Guideline Status First-line / Mainstay Not routine in T2DM
Primary Fetal Risk ↓ Macrosomia / LGA ↑ SGA potential
Maternal Benefit Precise dose titration ↓ Weight gain · ↓ Insulin dose
Key Trial Evidence Multiple RCTs; established safety MiTy trial (T2DM-specific)

GLP-1 Receptor Agonists Must Be Stopped Before or at Conception

🚫
GLP-1 RA
Insufficient fetal safety data — teratogenicity cannot be excluded
Discontinue prior to conception or immediately upon confirmation
Transition to insulin under MFM / endocrinology guidance
Metformin: safe regarding malformation risk in first trimester

Pregnancy Can Worsen Pre-Existing Diabetic Complications

👁 Retinopathy
Baseline ophthalmology evaluation at first visit.

Rapid progression possible during pregnancy — monitor each trimester.
🫘 Nephropathy
Baseline creatinine, GFR, and urine protein/creatinine ratio.

Nephropathy significantly elevates preeclampsia risk.
❤ Cardiovascular
Baseline ECG if longstanding T2DM.

Hypertension management critical throughout gestation.

Evaluate all end-organ complications at the first prenatal visit

Low-Dose Aspirin from 12 Weeks Is Standard of Care

💊
150 mg/day
Low-dose aspirin
Pre-gestational T2DM = high preeclampsia risk category
Initiate at 12 weeks gestation
Continue until 36–37 weeks per ACOG/SMFM guidance
Evening dosing preferred for maximal efficacy
First visit
8–10 wks
Start aspirin
12 wks
Stop aspirin
36–37 wks
Delivery
39 wks

Serial Growth Ultrasounds Detect Both Macrosomia and Growth Restriction

Surveillance Timing Indication
Anatomy ultrasound 18–22 weeks Congenital anomaly screening
Serial growth ultrasound Every 4 weeks from 28 wks Macrosomia and growth restriction
Increased growth frequency Every 2–3 weeks If metformin used (SGA risk)
NST / BPP Weekly from 32–36 wks Vascular complications or poor control
Umbilical artery Doppler As indicated Suspected growth restriction

Surveillance intensity individualized based on glycemic control and complication status

Well-Controlled T2DM: Deliver at 390/7–396/7 Weeks

36 wks
Stop aspirin
37–38 wks
Earlier if complications
390/7–396/7
Well-controlled
Well-Controlled, No Complications
Deliver 390/7–396/7 weeks. Individualize mode of delivery.
Vascular Complications / Poor Control
Earlier delivery indicated. Timing per MFM/obstetric team assessment.

Insulin Requirements Drop Precipitously After Placental Delivery

Delivery High Low Antepartum Postpartum ↓
Insulin dose over time
Placental delivery removes insulin resistance — doses drop immediately
Significant dose reduction required; monitor closely for hypoglycemia
Breastfeeding further lowers insulin requirements
Resume or adjust pre-pregnancy regimen; endocrinology follow-up essential

Five Pillars of Pre-Gestational T2DM Management

1
🎯
Optimize HbA1c
< 6.5% before conception
2
💉
Insulin first-line;
metformin not routine in T2DM
3
📊
Stringent glucose targets
throughout pregnancy
4
💊
Low-dose aspirin
from 12 weeks
5
🔍
Serial surveillance +
individualized delivery planning
ACOG SMFM Endocrine Society 2024–2025
1 / 15